Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose

Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes (T2D) already taking metformin and in those who were previously untreated.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Diabetes empagliflozin/linagliptin Latest News metformin sustained efficacy type 2 diabetes Source Type: news